Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07069738 · ClinicalTrials.gov registry record · NA
Safety and Effectiveness of Left Bundle Branch Area Pacing Versus Conventional Cardiac Resynchronization Therapy in Heart Failure
A NA study of Heart Failure - NYHA II - IV, sponsored by Boston Scientific Corporation.
- Recruiting
- Registry status
- NA
- Development phase
- 850
- Enrollment target
- 18
- Study locations
NCT07069738 is a NA study of Heart Failure - NYHA II - IV that is actively recruiting participants, run by Boston Scientific Corporation. The registered enrollment target is 850 participants. The trial reports 18 study locations across 13 states.
The verdict
NCT07069738, a NA study of Heart Failure - NYHA II - IV, is actively recruiting participants, sponsored by Boston Scientific Corporation.
- RECRUITING
- Registry status
- NA
- Development phase
- 850 participants
- Enrollment target
- 18
- Study locations
Study Summary
This study will compare two different methods to pace the heart to treat heart failure including: 1. The current standard method of implanting a pacing lead in a vein on the surface of the left lower chamber of the heart (left ventricle) to deliver heart failure therapy. This method is called Cardiac Resynchronization Therapy (CRT). 2. The other method is using a lead implanted in the Left Bundle Branch Area (LBBA) of your heart. This method is called Left Bundle Branch Area Pacing or LBBAP. This lead is approved by the Food and Drug Administration (FDA) to be implanted in this area of the heart, but not to provide heart failure treatment.
Conditions Studied
Interventions
- DEVICE CRT-D with a Quadripolar LV lead
- DEVICE CRT-D with INGEVITY+ pace/sense lead
Study Locations (18)
New York
- New York Hospital Queens - Flushing
- Weill Cornell Medical University - New York
- Rochester General Hospital - New York
Alabama
- Heart Center Research, LLC - Huntsville
- Mobile Infirmary Medical Center - Mobile
California
- Alta Bates Summit Medical Center - Oakland
- Cardiology Associates Medical Group, Inc. - Ventura
Minnesota
- St. Mary's Duluth Clinic Regional Heart Center - Duluth
- Centracare Heart and Vascular Center - Saint Cloud
Arkansas
- Arrhythmia Research Group - Jonesboro
Florida
- Sarasota Memorial Hospital - Sarasota
Georgia
- Emory University Hospital - Atlanta
Illinois
- Midwest Cardiovascular Institute - Naperville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 850 participants |
| Start Date | 2025-10-22 |
| Est. Completion | 2029-11 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07069738
The ClinicalTrials.gov registry entry for NCT07069738 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 850 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Scientific Corporation, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Heart Failure - NYHA II - IV appearing as the primary indexed condition, and to 2 interventions - of which CRT-D with a Quadripolar LV lead is the first listed.
NCT07069738 reports 18 study locations spanning 13 distinct geographic areas - top geographies include New York, Alabama, California.
Frequently Asked Questions
What is clinical trial NCT07069738 about?
NCT07069738 is a clinical study titled "Safety and Effectiveness of Left Bundle Branch Area Pacing Versus Conventional Cardiac Resynchronization Therapy in Heart Failure". This study will compare two different methods to pace the heart to treat heart failure including: 1. The current standard method of implanting a pacing lead in a vein on the surface of the left lower chamber of the heart (left ventricle) to deliver heart failure therapy. This method is called Cardi...
What is the current status of trial NCT07069738?
This trial is currently recruiting. It is a NA study. The enrollment target is 850 participants. The study started on 2025-10-22. Estimated completion is 2029-11.
What conditions does trial NCT07069738 study?
This clinical trial studies the following conditions: Heart Failure - NYHA II - IV.
What interventions are being tested in trial NCT07069738?
The interventions under investigation include: CRT-D with a Quadripolar LV lead (DEVICE), CRT-D with INGEVITY+ pace/sense lead (DEVICE).
Who is sponsoring clinical trial NCT07069738?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07069738 being conducted?
This trial has 18 study locations across Alabama, Arkansas, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure - NYHA II - IV
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.